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Enhanced radiosensitivity in experimental tumours
following erythropoietin treatment of chemotherapy-
induced anaemia
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Summary The radiosensitivity of solid tumours in anaemic rats treated with recombinant human erythropoietin (rhEPO, epoetin beta) was
studied. Anaemia was induced by a single dose of carboplatin (45 mg kg-' i.v.), resulting in a reduction in the haemoglobin concentration by
30%. In a second group, the development of anaemia was prevented by rhEPO (1000 IU kg-1) administered s.c. three times per week starting
6 days before the carboplatin application. Three days after carboplatin treatment, DS-sarcomas were implanted subcutaneously onto the hind
foot dorsum. Neither carboplatin nor rhEPO treatment influenced tumour growth rate. Five days after implantation, tumours were irradiated
with a single non-curative dose (10 Gy), resulting in a growth delay with a subsequent regrowth of the tumours. In the rhEPO-treated group,
the growth delay lasted significantly longer (9.5 days vs. 4.5 days) and the regrowth was slower (6.0 days vs. 4.1 days) compared with the
anaemic group. These data suggest that the correction of chemotherapy-induced anaemia by rhEPO (epoetin beta) treatment increases
tumour radiosensitivity, presumably as a result of an improved oxygen supply to tumour tissue.
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Anaemia is a common phenomenon in clinical oncology which
can be caused by the neoplastic disorder itself [due to, for
example, deficiency oferythropoietic factors, bone marrow inhibi-
tion by inflammatory cytokines, haemolysis, bone marrow infiltra-
tion or paraneoplastic syndromes (for a review see Levine et al,
1993; Spivak, 1994)], by myelosuppressive therapy modalities or
by acute or chronic bleeding of the tumour. The anaemia can
severely affect the general well-being of the patient and may limit
the applicability and efficacy of several anti-tumour therapy
modalities. Numerous studies have shown a strong relationship
between the therapeutic outcome ofradiotherapy and haemoglobin
concentrations, indicating that anaemic patients have a poorer
prognosis following standard radiotherapy [for reviews see (Grau
et al, 1998; Levine et al, 1993)].
The diminished therapeutic effect of radiotherapy in anaemic
patients might be a result ofthe reduced oxygen-carrying capacity
ofthe blood, which in turn decreases the arterial oxygen supply to
the tumour. Thus, severe anaemia will result in a poorer oxygena-
tion status, further increasing the hypoxia already present in many
tumours (Vaupel et al, 1989). In a recent study, Kelleher et al
(1996) demonstrated that anaemia leads to a significantly lower
median tumour PO2 and a higher fraction of hypoxic pO values.
At the same time, tumour hypoxia or anoxia protects tumour cells
from sparsely ionizing radiation and thus reduces the efficacy of
radiotherapy (Bush et al, 1978).
With this in mind, several studies have investigated the effect of
correcting anaemia by homologous blood or red blood cell (RBC)
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transfusion on tumour oxygenation (Kelleher et al, 1995) and the
outcome of radiotherapy (Levine et al, 1993; Grau et al, 1998).
However, these studies have not been able to show definitive
improvements in radiosensitivity when anaemia was corrected,
possibly because of the recruitment of patients with already
advanced diseases (Levine et al, 1993). Furthermore, blood or
RBC transfusion carries a risk of infection transmission and may
cause alloimmunization and allergic reactions (Spivak, 1994).
The treatment of anaemic tumour patients with recombinant
human erythropoietin (rhEPO) is an alternative to blood transfu-
sion. Besides improving the general well-being of the patient,
rhEPO may increase the oxygen-carrying capacity of blood and
thus improve tumour oxygenation, as demonstrated by Kelleher et
al (1996). However, to date no conclusive studies have been
performed investigating the effect of anaemia correction with
rhEPO treatment on the radiosensitivity of tumours. In the present
study, the effect of preventing a chemotherapy-induced anaemia
by rhEPO (epoetin beta) treatment on the radiosensitivity ofexper-
imental rat tumours has therefore been studied.
MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats (Charles River Wiga, Sulzfeld,
Germany; body weight 140-170 g) housed in our animal care
facility were used in the study. Animals were allowed access to
food and acidified water ad libitum before and throughout the
investigation. All experimentation had previously been approved
by the regional animal ethics committee and was conducted
according to German federal law.
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Tumours
Solid DS-sarcomas were induced by injecting DS-sarcoma cells
(0.4 ml, approximately 104 cells ,ul-') subcutaneously into the hind
food dorsum. Tumours grew as flat, spherical segments and
replaced the subcutis and corium completely. Tumour volumes
were determined by measuring the three orthogonal diameters of
the tumour and using an ellipsoid approximation with the formula
V=d, x d, x d3 x ic/6. From the volume growth curves, the volume
doubling time was calculated during exponential tumour growth.
Drugs
A prolonged anaemia was induced in all animals by a single i.v. dose
of carboplatin (Sigma-Aldrich, Steinheim, Germany; 45 mg kg-'
body weight dissolved in isotonic saline at a concentration of
20 mg ml-') into the tail vein 3 days before tumour implantation.
Recombinant human erythropoietin (epoetin beta, Recormon,
purity >98%, Boehringer-Mannheim, Mannheim, Germany) was
dissolved in isotonic saline and administered (1000 IU kg-') three
times per week over 14 days by s.c. injection starting 9 days before
tumour implantation. Control animals received equivalent
volumes of the solvent. Studies in rats have shown that there is no
significant production of antibodies against rhEPO over this treat-
ment period (W Rebel, personal communication).
Radiation treatment
Tumours were irradiated locally on day 5 after implantation with a
single dose of 10 Gy using conventional 100-kV X-rays at a dose
rate of 14 Gy min-'. The tube was placed 5-10 mm above the
tumour and the field was approximately 4 x 4 cm2. Irradiation was
carried out under pentobarbital anaesthesia (40 mg kg-' body
weight i.p.; Nembutal, Sanofi Ceva, Paris, France) in animals
spontaneously breathing room air and placed supine on an
isolating polystyrene block to avoid decreases in core temperature.
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Figure 1 Time course of the haemoglobin concentration (cHb) in animals
treated only with a single dose of carboplatin on day -3 (A) and animals
additionally treated with rhEPO (from day -9 until day +5, three times a
week) (0). Day 0 is the day of tumour implantation. Each point represents
data from at least eight animals. (**)P < 0.01. Arrows indicate the times of
rhEPO and carboplatin administration as well as of tumour implantation (TI)
and irradiation
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Experimental groups
The experimental groups can be summarized as follows:
Group 1 (anaemic, irradiated): animals treated 3 days before
tumour implantation with carboplatin and irradiated on day 5 after
implantation with a single dose of 10 Gy (n = 8).
Group 2 (non-anaemic, irradiated): animals treated with rhEPO
(epoetin beta) three times per week from 9 days before irradiation
and up until the day of irradiation. Carboplatin was administered
on day -3 and tumours were irradiated on day 5 with a single dose
of 10 Gy (n = 9).
Group 3 (anaemic, non-irradiated): animals treated with carbo-
platin as in group 1 but not irradiated (n = 8).
Group 4 (non-anaemic, non-irradiated): animals treated with
rhEPO (epoetin beta) and carboplatin as in group 2 but not irradi-
ated (n = 7).
Data were collected from two identical but temporally indepen-
dent sets of experiments, whereby all treatment groups were
included in each set to ensure reproducibility ofthe results.
Measurements
Erythrocyte and leucocyte parameters were assessed using a
multiparameter, automated haematology analyser (Cell-Dyn 3500;
Figure 2 Tumour volume growth in anaemic animals treated with
carboplatin (A) and animals in which carboplatin-induced anaemia was
prevented by preceding treatment with rhEPO (0). Each data point
represents a minimum of 12 tumours
Abbott, Wiesbaden, Germany) measuring erythrocyte, white blood
cell and platelet count together with the mean cell volume by an
impedance technique and the haemoglobin concentration by a
photometric method (at 540 nm). In addition, the analyser uses the
measured values to calculate several other parameters (e.g.
haematocrit, mean corpuscular haemoglobin content and mean
corpuscular haemoglobin concentration). All measurements were
performed using a sample of venous blood (130 ,tl) taken from the
animal's tail.
Statistical analysis
Results are expressed as means ± standard error of the mean
(s.e.m.). Differences between the groups were assessed by two-
tailed Wilcoxon test for unpaired samples. The significance level
was set at oc = 5% for all comparisons. For characterizing the effect
of radiotherapy on tumour growth, the growth delay induced by
irradiation was calculated.
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RESULTS
Starting at a mean haemoglobin concentration of approximately
130 g 1-', a single dose ofcarboplatin (45 mg kg-' body weight i.v.)
resulted in pronounced anaemia in rats with a mean haemoglobin
concentration (cHb) of about 90 g 1-1, 8 days after application. The
haemoglobin level remained at this reduced level for at least 7
days (Figure 1) before gradually recovering to normal values over
a period of 20 days (data not shown). Continuous treatment with
rhEPO (epoetin beta) in otherwise untreated rats increases the cHb
within I week from 132 g 1-' to 149 g 1-1 (Figure 1). A subsequent
application of carboplatin 6 days after commencement of rhEPO
therapy reduces the haemoglobin level within 8 days to values
comparable to the cHb before rhEPO treatment. Withdrawal of
further rhEPO (epoetin beta) application led to the further develop-
ment of anaemia down to levels ofcontrol animals not treated with
rhEPO (Figure 1). Thus, rhEPO therapy for 6 days before carbo-
platin application results in prevention of the chemotherapy-
induced anaemia at the time of irradiation.
The volume growth curves in the anaemic control group and the
group in which anaemia was prevented by rhEPO treatment were
identical, with a volume doubling time of2.4 ± 0.1 days independent
ofthe actual cHb or treatment with rhEPO for 14 days (Figure 2).
In Figure 3, the tumour growth curve is shown for both groups
when tumours were irradiated on day 5 after tumour implantation.
Both curves initially show a further volume increase after irradia-
tion, which is then followed by a slight shrinkage of the tumour.
After a period of5-7 days, the tumours began to regrow. On the day
of irradiation, RBC-related parameters were significantly different
between the two treatment groups (Table 1), with the group treated
only with carboplatin showing a mean haemoglobin concentration
of 90 g 1-' and the group in which anaemia was prevented by
previous rhEPO (epoetin beta) treatment showing a cHb of 127 g 1-'
(comparable to the cHb ofthe pretreatment period). In both groups,
the parameters describing characteristics of single erythrocytes
(mean cell volume, mean corpuscular haemoglobin content and
mean corpuscular haemoglobin concentration) showed no differ-
ence and are within the normal range, indicating a normocytic,
normochromic anaemia induced by carboplatin (Table 1). After
irradiation, the tumour growth rate was significantly different
between the groups (Figure 3), with tumours in anaemic animals
regrowing faster than in non-anaemic animals (volume doubling
time during the regrowth period was 4.1 days in the anaemic group,
with 1 out of 12 tumours showing regression after irradiation; and
6.0 days in the non-anaemic, rhEPO-treated group with 4 out of 18
tumours showing regression). The regrowth after irradiation also
starts later in the epoetin beta group, resulting in a growth delay (at
the 1.3 ml tumour volume level) of approximately 9.5 days
compared with 4.5 days in the anaemic group and 12.0 days in non-
anaemic control animals (data not shown).
DISCUSSION
Carboplatin at an i.v. dose of 45 mg kg-' body weight induces a
pronounced and prolonged normochromic, normocytic anaemia.
At this dose, the mean haemoglobin concentration is reduced by
about 30% of the control level with a nadir on day 11 (data not
shown) and a pronounced variability ranging from 42 to 125 g 1-'.
The dose used is close to the maximally tolerated dose of carbo-
platin (60 mg kg-' body weight i.v.) (Siddik et al, 1987). The data
Table 1 RBC-related parameters on the day of irradiation in the anaemic
carboplatin group and the carboplatin group in which anaemia was
prevented by rhEPO (epoetin beta) treatment. Additionally, for comparison,
values in non-anaemic, untreated animals are given. (n = number of animals;
P-values for the comparison of anaemic control vs. rhEPO group)
Carboplatin- Carboplatin Untreated
treated +rhEPO- controls
treated
n 8 9 7
cHb(gl-1) 90+8 127±5 137±7
P= 0.0017
Haematocrit (%) 31 + 3 45 + 1 42 + 1
P= 0.0009
RBC count (106 ,ul-') 4.7 0.4 6.5 0.2 7.0+0.2
P= 0.0009
Mean corpuscular volume 66 ± 1 69 + 2 60 + 1
(MCV) (fl) n.s.
Mean corpuscular haemoglobin 19 + 1 20 + 1 20 + 1
(MCH) (pg) n.s.
Mean corpuscular cHb 287 + 5 284 ± 5 330 ± 2
(MCHC) (g l-1) n.s.
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Figure 3 Tumour volume growth in animals with carboplatin-induced
anaemia (A) and animals in which anaemia was prevented by preceding
treatment with rhEPO (0). All tumours were irradiated with a single dose of
10 Gy on day 5. Each data point represents a minimum of 12 tumours.
Arrows indicate the times of rhEPO administration and irradiation. *P < 0.05,
**P < 0.01
on carboplatin-induced anaemia obtained in the present study are
in good accordance with observations made by other investigators
(Siddik et al, 1987; Ohno et al, 1993), describing a dose-dependent
induction of anaemia with carboplatin doses between 40 and
60 mg kg-'. Although Siddik et al (1987) concluded that internal
haemorrhaging as a result of thrombocytopenia causes the carbo-
platin-induced anaemia, no signs ofsevere bleeding were observed
in the present study. Similarly, carboplatin-induced anaemia has
also been attributed to myelosuppression. However, rhEPO treat-
ment has been shown to be effective in increasing the haemoglobin
concentration in these carboplatin-treated patients (Markman et al,
1993; de Campos et al, 1995). In the present study, rhEPO was
able to prevent anaemia if it was administered before carboplatin.
However, if carboplatin was given first and anaemia therefore
already present, rhEPO treatment could only slightly improve the
RBC-related parameters (data not shown).
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As many chemotherapeutic agents are myelosuppressive, the
anaemia model used in the present study describes a realistic situ-
ation of patients undergoing a combined radiochemotherapy. The
model of a tumour-associated anaemia developed earlier by our
group (Kelleher et al, 1996) could not be applied to the present
study, as the ascites tumour used to induce anaemia cannot be used
for an observation period greater than 6-8 days.
The carboplatin treatment 3 days before tumour implantation
had no effect on the growth rate of the DS-sarcoma. The volume
doubling time of 2.4 days found in the non-irradiated group is in
good accordance with previous data obtained for this tumour
model (Busse et al, 1995). As the biological half-life of carbo-
platin is about 3-4 h in humans (Reece et al, 1987), and the
turnover is somewhat higher in rats, it can be assumed that on the
day of tumour implantation no appreciable amounts ofcarboplatin
are present in the animals, and therefore effects of carboplatin on
tumour growth in this model are not to be expected.
As the growth curves of the non-irradiated rhEPO and control
group are not different, it can be concluded that rhEPO per se has
no effect on the growth rate of tumours. Joiner et al (1993) found
in an in vivo study a slight slowing of tumour growth rate in the
first days following implantation in a mouse model treated with
higher rhEPO doses. Thereafter, tumour growth rate did not differ
between the groups.
Tumour growth in chronically hypoxic animals is slower
(Tannock et al, 1970). The significantly reduced tumour growth
rate in anaemic animals observed by McCormack et al (1990) has,
therefore, been attributed to increases in tumour hypoxia. In the
present study, no evidence was found for differences in tumour
growth between anaemic animals and rhEPO-treated anaemic
animals, as was the case in our earlier study with a tumour-induced
anaemia (Kelleher et al, 1996). The differences between the find-
ings of McCormack's and our group cannot be explained. Factors
such as tumour blood flow and blood rheology may play a role and
warrant further investigation.
Several studies have been performed to analyse the effect of
anaemia on the radiosensitivity of solid tumours. However, the
results ofthese studies are not unanimous, describing an increase in
radioresistance (Hewitt et al, 1971; Hill et al, 1972; Hirst et al,
1984; McCormack et al, 1990), no effect on the outcome of radio-
therapy (Hirst et al, 1984; Joiner et al, 1993) but also an increase in
radiosensitivity (Rojas et al, 1987). One major factor affecting
radioresistance during anaemia seems to be the period of time over
which anaemia occurred. Pronounced differences were seen
between studies in which anaemia was acutely (Hewitt et al, 1971;
Hirst et al, 1984) or chronically (Hirst et al, 1984; Rojas et al, 1987;
Joiner et al, 1993) induced. From these data, it seems obvious that
physiological adaptation to haematocrit changes plays a role in the
effect of anaemia on radiosensitivity. Another factor influencing
the results might be the application ofirradiation as a single dose or
in a fractionated schedule (Hirst et al, 1984; Rojas et al, 1987).
On the basis ofthese findings, several studies have investigated
the effect of correcting anaemia on sensitivity to radiotherapy
(Hewitt et al, 1971; Hill et al, 1972; Hirst et al, 1984; Rojas et al,
1987; Joiner et al, 1993), whereby in most ofthese studies blood or
RBC transfusion was used to compensate for anaemia. Studies on
the effects of transfusion on radioresistance have generally shown
an improvement in radiotherapy with increases in haemoglobin
concentration (Hewitt et al, 1971; Hirst et al, 1984; Rojas et al,
1987). This effect was even seen in a study in which anaemia
initially increased the radiosensitivity (Rojas et al, 1987).
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Most studies of the effect of rhEPO on the anaemic state during
radiotherapy have generally only focused on changes in RBC-
related parameters (Lavey et al, 1993; Vijayakumar et al, 1993)
and did not examine changes in radiosensitivity. Only Joiner et al
(1993) used rhEPO to correct a tumour-associated anaemia and
measured radiosensitivity in anaemic animals as well as in mice
in which anaemia was treated with different doses of rhEPO.
However, the anaemia model Joiner et al used (carcinoma NT in
CBA mice) results in only moderate anaemia with a haematocrit of
38%. The correction of the anaemia by rhEPO (20 U daily) led
to a haematocrit of 65%, an overcompensation which can be
interpreted as a rhEPO-induced polycythaemia. It is questionable
whether a haematocrit of 38% would result in a reduction in the
oxygen transport capacity, which in turn could appreciably
increase tumour hypoxia. At the same time, the rheological prop-
erties ofblood at a haematocrit of65% could result in a decrease in
tumour perfusion, as seen by Joiner et al, (1993), which might lead
to a reduction in oxygen supply to the tumour. Thus the overcom-
pensation ofanaemia in that study could be the reason for a lack of
improvement in radiosensitivity. In the present study, the anaemia
group showed a haematocrit of 31 % and after correction by rhEPO
of 45%. At these levels, anaemia has a measurable impact on the
oxygenation of the DS-sarcoma (Kelleher et al, 1996). Here, the
fraction ofpO, values between 0 and 2.5 mmHg (indicating less
than half-maximum radiosensitivity) was 76 ± 3% for anaemic
animals and 55 ± 3% for animals in which anaemia was prevented
by rhEPO treatment, at a tumour volume comparable to that
used in this study on the day of irradiation. These differences
(P < 0.001) in the fraction of hypoxic pO,-values might explain
the increase in radiosensitivity seen following rhEPO in this study.
In conclusion, the present study has demonstrated that correc-
tion of a clinically relevant anaemia (cHb approximately 90 g 1-')
by treatment with rhEPO (epoetin beta) can significantly increase
the radiosensitivity of solid growing DS-sarcomas, tumours
showing pronounced hypoxia even under non-anaemic control
conditions (Kelleher et al, 1996). These results form a basis for
further studies on improving the outcome of radiotherapy in
anaemic patients by rhEPO treatment, especially in patients in
whom tumours are known to be hypoxic. In particular, the schedule
of rhEPO treatment should be further investigated, for example to
assess whether administration of rhEPO after chemotherapy is
necessary to obtain the same radiosensitizing effect.
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